Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides
about
Fruit juice inhibition of uptake transport: a new type of food-drug interactionOATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamiliesEvidence of reduced oral bioavailability of paracetamol in rats following multiple ingestion of grapefruit juiceSimultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activitiesFexofenadine/cyclodextrin inclusion complexation: phase solubility, thermodynamic, physicochemical, and computational analysis.Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon CalcitoninValidation and application of a liquid chromatography-tandem mass spectrometric method for quantification of the drug transport probe fexofenadine in human plasma using 96-well filter plates.A modified grapefruit juice eliminates two compound classes as major mediators of the grapefruit juice-fexofenadine interaction: an in vitro-in vivo "connect"Influence of dietary substances on intestinal drug metabolism and transport.Impact of OATP transporters on pharmacokinetics.The effect of grapefruit juice on drug disposition.Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders.Determination of fexofenadine in Hank's balanced salt solution by high-performance liquid chromatography with ultraviolet detection: application to Caco-2 cell permeability studies.Effects of grapefruit juice on the pharmacokinetics of acebutolol.Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide.Transporters and their impact on drug disposition.Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport.Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.Transporter-mediated drug interactions: clinical implications and in vitro assessment.Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs.Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption.Role of OATP transporters in the disposition of drugs.Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.Rapid Quantitation of Furanocoumarins and Flavonoids in Grapefruit Juice using Ultra-Performance Liquid ChromatographyAnalysis of drug interactions involving fruit beverages and organic anion-transporting polypeptides.Clinical pharmacokinetics of fexofenadine enantiomers.Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapyFexofenadine hydrochloride in the treatment of allergic disease: a reviewRole of transporters in drug interactions.Potential risks resulting from fruit/vegetable-drug interactions: effects on drug-metabolizing enzymes and drug transporters.Pharmacokinetic drug interactions involving Ginkgo biloba.Intestinal transporters: enhanced absorption through P-glycoprotein-related drug interactions.In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.Enzyme- and transporter-mediated beverage-drug interactions: An update on fruit juices and green tea.Challenges in oral peptide delivery: lessons learnt from the clinic and future prospects.Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy.CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease.Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia.Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites.
P2860
Q24630998-2272B007-519A-4C06-AC17-11A7429FE9C6Q27001267-3F1ADCBB-C298-4D71-9150-49337E53D0A8Q28254692-71A957CB-CDDD-4098-B604-E8F812D2221AQ28269209-1FC32250-9926-4BB4-9D7E-74C53BFCFAC7Q31138854-AF582943-C6C3-46BA-9AB0-AB02179A3EE2Q33368276-50475B13-DD7E-4E83-8F21-32692730D5B2Q33639593-A0145A83-D4B5-4D09-AA5D-F6EDDF2E34F2Q33645582-BDA1B44C-41BF-4A00-9071-A972933547CFQ34553835-0C145D6E-A85A-494C-B172-A75354A317E4Q34612244-9AF4E287-3A41-43FD-BDD3-1DA63A79B0ECQ34764136-9129EF99-AE6D-4932-ADC3-9A7F6E8E7AFDQ34988193-C6EA45A2-F024-4F90-A7D4-79CA5196A331Q35232517-7E5FE16C-79F8-4BBC-B474-FB407166C124Q35827056-63289846-800E-4AA6-9D1B-3EDF86A8FD63Q35827580-ECB3A12A-EA07-4334-9D30-BDA749AB4974Q36024467-CD4FAEE9-2454-4B11-88C9-455B6FA31FA1Q36123304-496B77EA-1641-4302-A6C1-8A692B7CBFC5Q36303746-7FAA6A5A-32D8-4F57-A5B2-8641B1451F61Q36641870-87B534B5-C808-4AFF-8AFB-E07BD8C7B607Q36725222-24CE7D21-4694-4DF4-972B-50B20BA321D9Q36795136-975C33F3-D2C9-4EFD-AEA9-9DC20DD12896Q37058658-E6923CE3-D509-4155-9E0F-D87C957E50C0Q37074085-DA97EDC5-67A6-4341-BF6C-E9F38744DCF8Q37121662-004C8650-95E9-4E2D-9741-DB1858198090Q37373966-11C46A5C-8E90-42B1-8E69-992F5775F7CFQ37605463-660CBC46-C657-4E18-A352-13767482EEEAQ37641373-1125BE4E-DAE0-4842-82B4-24836EFD2DE3Q37735146-F57313F8-AE9E-4E66-B0EC-D4078E935564Q37857671-C72225B0-8123-4C8E-B519-5E8A610EEC0AQ37964577-7B56B18A-E0A9-43E9-B967-A3B4DC290950Q37993631-CDF457FF-23A6-408F-80E7-BD2945765508Q38122439-F458791A-4B23-4910-A7B8-8F5FF622AFE0Q38202698-A8798CD5-1574-44B3-9ECB-236D2FA31549Q38214334-474C11F5-A853-474A-959A-84CB94C4FAEEQ38533636-8134F4F9-7397-4186-B1EA-FF622581FD64Q38653884-54F2602B-D24B-45CC-85E2-BF2F5F634DE5Q38888350-6034CDD8-EF46-4941-B57A-1CF575524405Q38903289-DE396B2E-5496-4F4A-9F65-04BCC814E41EQ39531941-6EC0D15E-E836-4B22-AAE4-3FEBCAAFC7ECQ39770558-93A8026D-3C4A-478F-B198-6AB32E1D4FE6
P2860
Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Effect of grapefruit juice vol ...... nion transporting polypeptides
@ast
Effect of grapefruit juice vol ...... nion transporting polypeptides
@en
Effect of grapefruit juice vol ...... nion transporting polypeptides
@nl
type
label
Effect of grapefruit juice vol ...... nion transporting polypeptides
@ast
Effect of grapefruit juice vol ...... nion transporting polypeptides
@en
Effect of grapefruit juice vol ...... nion transporting polypeptides
@nl
prefLabel
Effect of grapefruit juice vol ...... nion transporting polypeptides
@ast
Effect of grapefruit juice vol ...... nion transporting polypeptides
@en
Effect of grapefruit juice vol ...... nion transporting polypeptides
@nl
P2093
P1476
Effect of grapefruit juice vol ...... nion transporting polypeptides
@en
P2093
David G Bailey
George K Dresser
Richard B Kim
P356
10.1016/J.CLPT.2004.10.005
P407
P577
2005-03-01T00:00:00Z